Acute Myeloid Leukemia | Tumor

FDA Grants Regular Approval to Venclexta Combo for Untreated Acute Myeloid Leukemia

October 16th 2020, 6:20pm


After granting accelerated approval in 2018, the Food and Drug Administration approved Venclexta in combination with Vidaza, Dacogen or low dose cytarabine in newly diagnosed patients with AML.

Adding Venclexta to Chemotherapy Improves Survival in Some with AML Who Are Ineligible for Standard Treatment

September 10th 2020, 1:00pm


Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.

FDA Approves Onureg for Continued Treatment of Adults with AML Who Achieved First Complete Remission

September 1st 2020, 5:45pm


The approval for patients with acute myeloid leukemia was based on data from the phase 3 QUAZAR AML-001 trial, which demonstrated that patients who received Onureg achieved a median overall survival of 24.7 months compared to 14.8 months for those who received placebo.

The Latest News and Updates in Acute Myeloid Leukemia

August 31st 2020, 3:00pm


A roundup of the latest news and updates for patients with acute myeloid leukemia from CURE®.

FDA Grants Novel Treatment for Acute Myeloid Leukemia Fast Track Designation

August 5th 2020, 5:00pm


The FDA’s fast track designation for BST-236 to treat adults aged 75 years or older with acute myeloid leukemia, or who have comorbidities that prevent the use of intensive induction chemotherapy, may open the doors to an accelerated approval.

Patient Assessment Tool May Provide Insight into Health-Related Quality of Life in AML

August 4th 2020, 7:00pm


A patient assessment tool, known as the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu), was a viable and valid outcome measure for patients with acute myeloid leukemia not eligible for intensive therapy.

Possible Triplet Regimen Shows Promise For Certain Patients with Acute Myeloid Leukemia

August 4th 2020, 5:00pm


“Overall, the take-home point is that it's a small study so far and the follow-up time is still short, but it is pretty exciting preliminary data,” said Dr. Courtney DiNardo about the combination of Tibsovo plus Venclexta – with or without Vidaza – in IDH1-mutated acute myeloid leukemia.

CURE Community Vlog: Having Great Purpose in Pain After Cancer

July 12th 2020, 10:00pm


“At 34, I have another chance to live the rest of my life with a consciousness that there's great purpose in the pain.”

Investigational Drug Combination Could Address Unmet Need in TP53-Positive MDS

June 19th 2020, 1:00am


The phase 3 trial evaluating eprenetapopt plus Vidaza completed enrollment recently, and could lead to a new standard of care with positive results, according to Dr. Guillermo Garcia-Manero.

FDA Expands Mylotarg Approval to Include Children With Newly-Diagnosed CD33-Positive AML

June 16th 2020, 8:37pm


The Food and Drug Administration (FDA) extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive acute myeloid leukemia (AML).